Earnings Feed
Start Free
Home/Filings/4/0000899243-15-008516
4//SEC Filing

Prothena Corp plc 4

Accession 0000899243-15-008516

$PRTACIK 0001559053operating
View on SEC.govCompany Profile

Filed

Nov 18, 7:00 PM ET

Accepted

Nov 19, 4:06 PM ET

Size

24.9 KB

Accession

0000899243-15-008516

Insider Transaction Report

Form 4
Period: 2015-11-17
Prothena Corp plcPRTA
Schenk Dale B.
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Ordinary Shares, par value $0.01 per share

    2015-11-17$6.03/sh+33,333$200,998→ 33,333 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2015-11-17$66.83/sh−9,826$656,655→ 18,207 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2015-11-17$68.65/sh−7,200$494,310→ 3,633 total
  • Gift

    Ordinary Shares, par value $0.01 per share

    2015-11-19+3,333→ 14,877 total(indirect: By Trust)
  • Exercise/Conversion

    Stock Option (right to buy)

    2015-11-17−33,333→ 383,334 total
    Exercise: $6.03Exp: 2023-01-29→ Ordinary Shares (33,333 underlying)
  • Gift

    Ordinary Shares, par value $0.01 per share

    2015-08-31−3,333→ 0 total
  • Gift

    Ordinary Shares, par value $0.01 per share

    2015-08-31+3,333→ 11,544 total(indirect: By Trust)
  • Sale

    Ordinary Shares, par value $0.01 per share

    2015-11-17$65.78/sh−5,300$348,623→ 28,033 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2015-11-17$67.89/sh−7,374$500,628→ 10,833 total
  • Sale

    Ordinary Shares, par value $0.01 per share

    2015-11-17$69.37/sh−300$20,810→ 3,333 total
  • Gift

    Ordinary Shares, par value $0.01 per share

    2015-11-19−3,333→ 0 total
Footnotes (9)
  • [F1]Represents transfer of shares to the Schenk Family Trust, dated 2/9/2004, of which Reporting Person is a Co Trustee with his spouse.
  • [F2]The shares are held by the Schenk Family Trust, dated 2/9/2004, of which Reporting Person is a Co Trustee with his spouse.
  • [F3]The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  • [F4]The transaction was executed in multiple trades in prices ranging from $65.34 to $66.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F5]The transaction was executed in multiple trades in prices ranging from $66.35 to $67.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F6]The transaction was executed in multiple trades in prices ranging from $67.36 to $68.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F7]The transaction was executed in multiple trades in prices ranging from $68.36 to $69.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F8]The transaction was executed in multiple trades in prices ranging from $69.36 to $69.375, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F9]The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship on each such vesting date.

Documents

1 file

Issuer

Prothena Corp plc

CIK 0001559053

→
Entity typeoperating
IncorporatedIreland

Related Parties

1
  • filerCIK 0001559053

Filing Metadata

Form type
4
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 4:06 PM ET
Size
24.9 KB
View on SEC.gov